Alcaftadine is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. This drug was approved in July 2010.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Trazodone | The risk or severity of QTc prolongation can be increased when Trazodone is combined with Alcaftadine. |
| Pitolisant | Alcaftadine may increase the QTc-prolonging activities of Pitolisant. |
| Lefamulin | Lefamulin may increase the QTc-prolonging activities of Alcaftadine. |
| Hydroxyzine | The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Hydroxyzine. |
| Ziprasidone | The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Ziprasidone. |
| Haloperidol | The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Haloperidol. |
| Fluoxetine | The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Alcaftadine. |
| Hyoscyamine | Alcaftadine may increase the anticholinergic activities of Hyoscyamine. |
| Ponesimod | The risk or severity of bradycardia can be increased when Ponesimod is combined with Alcaftadine. |
| Fexinidazole | The risk or severity of adverse effects can be increased when Alcaftadine is combined with Fexinidazole. |
| Tenofovir alafenamide | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Alcaftadine. |
| Clozapine | The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Clozapine. |
| Glasdegib | The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Glasdegib. |
| Vilanterol | The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Alcaftadine. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Alcaftadine. |
| Quizartinib | The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Quizartinib. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Citalopram. |
| Pimavanserin | The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Pimavanserin. |
| Gepirone | The risk or severity of QTc prolongation can be increased when Gepirone is combined with Alcaftadine. |
| Etrasimod | The risk or severity of QTc prolongation and torsade de pointes can be increased when Etrasimod is combined with Alcaftadine. |
| Bedaquiline | The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Bedaquiline. |
| Encorafenib | The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Alcaftadine. |
| Givinostat | The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Givinostat. |
| Inotuzumab ozogamicin | The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Inotuzumab ozogamicin. |
| Mavorixafor | The risk or severity of QTc prolongation can be increased when Mavorixafor is combined with Alcaftadine. |
| Ribociclib | The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Alcaftadine. |
| Revumenib | The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Revumenib. |